Sali, Rhabeah B.
HRN: 25-76-38 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/15/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/15/2024
10/22/2024
IV
44 MG
EVERY 24 HOURS
SEPSIS
Waiting Final Action
Indication: Empiric Type of Infection: Unspecified Sepsis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes